Takeda Pharmaceutical (NYSE:TAK) Downgraded to Hold Rating by Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other research firms also recently issued reports on TAK. Weiss Ratings reissued a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Wednesday, April 29th. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Finally, Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Takeda Pharmaceutical currently has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

TAK stock opened at $15.63 on Friday. The stock has a 50-day moving average price of $16.43 and a two-hundred day moving average price of $16.74. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90. The company has a current ratio of 1.09, a quick ratio of 0.70 and a debt-to-equity ratio of 0.59. The company has a market cap of $49.76 billion, a PE ratio of 40.09 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. As a group, research analysts predict that Takeda Pharmaceutical will post 0.94 EPS for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of large investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its position in Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock worth $6,558,000 after acquiring an additional 43,706 shares in the last quarter. AQR Capital Management LLC grew its position in Takeda Pharmaceutical by 43.6% in the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after acquiring an additional 59,442 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after acquiring an additional 692,404 shares in the last quarter. Focus Partners Wealth raised its stake in shares of Takeda Pharmaceutical by 4.1% during the first quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after purchasing an additional 3,239 shares during the period. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Takeda Pharmaceutical during the second quarter valued at approximately $351,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.